Grand Decade and existing investor Boehringer Ingelheim Venture Fund helped supply $38.2m for the mRNA immunotherapy developer and Vrije Universiteit Brussel spinout.

Belgium-based RNA immunotherapy developer EtheRNA secured €34m ($38.2m) on Tuesday in a series B round featuring pharmaceutical companies Boehringer Ingelheim and China Grand. Financial services firm BNP Paribas also took part, though its BNP Paribas Fortis Private Equity vehicle, as did LSP, Omega Funds, PMV, Yijing Capital, Fund+ and Novalis LifeSciences. The corporates invested through…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.